There are currently 2708 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
06/27/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Metastatic Prostate Cancer
Register for Updates
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312
Recruiting
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
06/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Polymyalgia Rheumatica
Register for Updates
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344
Recruiting
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Register for Updates
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
NCT06581198
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/27/2025
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Research Site, Boston, Massachusetts +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
NCT06492304
Recruiting
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: Research Site 3, Boston, Massachusetts
Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Register for Updates
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251
Recruiting
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/27/2025
Locations: New England Baptist Hospital, Boston, Massachusetts
Conditions: Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Register for Updates
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06406114
Recruiting
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Register for Updates
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358
Recruiting
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Partici... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Register for Updates
Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)
NCT07047209
Recruiting
This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: MGH, Boston, Massachusetts
Conditions: ALS (Amyotrophic Lateral Sclerosis)
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
Recruiting
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/27/2025
Locations: Copley Clinical, Boston, Massachusetts
Conditions: Generalized Anxiety Disorder
Register for Updates
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231
Recruiting
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Multiple System Atrophy
Register for Updates